Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.55 |
| ▸ | MGAM | O43451 | 4/20 | 0.55 |
| ▸ | SI | P14410 | 3/20 | 0.55 |
| ▸ | GBA1 | P04062 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LCT | P09848 | 1/20 | 0.55 |
| ▸ | AGL | P35573 | 3/20 | 0.52 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.38 |
| ▸ | UGCG | Q16739 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325136 | 1.00 | GAA (0.55) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL941922 | 1.00 | GAA (0.55) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL17795748 | 1.00 | GAA (0.55) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL941202 | 0.81 | GBA2 (0.57) | GAAMGAMSIGBA1AGL | |
| SCHEMBL12325138 | 0.81 | GBA2 (0.57) | GAAMGAMSIGBA1AGL | |
| SCHEMBL12289779 | 0.81 | GBA2 (0.57) | GAAMGAMSIGBA1AGL | |
| SCHEMBL4166086 | 0.78 | AGL (0.52) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL12191646 | 0.78 | GAA (0.51) | GAAMGAMSIGBA1AGL | |
| SCHEMBL12327271 | 0.73 | GAA (0.48) | GAAMGAMSIGBA1AGL | |
| Piperidine SCHEMBL3381522 | 0.72 | GBA2 (0.50) | GAAMGAMSIGBA1AGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GAA 1/4885MGAM 36/4885SI 230/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GAA 107/4885MGAM 43/4885SI 219/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | GAA 268/4885MGAM 97/4885SI 388/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | GAA 268/4885MGAM 97/4885SI 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.